ES2619936T3 - Stable and filterable enveloped virus formulations - Google Patents
Stable and filterable enveloped virus formulations Download PDFInfo
- Publication number
- ES2619936T3 ES2619936T3 ES05817250.3T ES05817250T ES2619936T3 ES 2619936 T3 ES2619936 T3 ES 2619936T3 ES 05817250 T ES05817250 T ES 05817250T ES 2619936 T3 ES2619936 T3 ES 2619936T3
- Authority
- ES
- Spain
- Prior art keywords
- volume
- weight
- ndv
- sucrose
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title description 27
- 238000009472 formulation Methods 0.000 title description 25
- 241000711404 Avian avulavirus 1 Species 0.000 claims abstract description 104
- 229930006000 Sucrose Natural products 0.000 claims abstract description 64
- 239000005720 sucrose Substances 0.000 claims abstract description 64
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 62
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 36
- 235000010355 mannitol Nutrition 0.000 claims abstract description 33
- 229930195725 Mannitol Natural products 0.000 claims abstract description 31
- 239000000594 mannitol Substances 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 28
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229920002307 Dextran Polymers 0.000 claims abstract description 23
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 20
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 12
- 239000010452 phosphate Substances 0.000 claims abstract description 12
- 230000003204 osmotic effect Effects 0.000 claims abstract description 11
- 229930195712 glutamate Natural products 0.000 claims abstract description 9
- 239000011780 sodium chloride Substances 0.000 claims abstract description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 7
- 239000001110 calcium chloride Substances 0.000 claims abstract description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 7
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 7
- 229920000136 polysorbate Polymers 0.000 claims abstract description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 6
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 5
- 239000000600 sorbitol Substances 0.000 claims abstract description 5
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 4
- 239000004472 Lysine Substances 0.000 claims description 50
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 38
- 239000004471 Glycine Substances 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 208000010359 Newcastle Disease Diseases 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 239000000243 solution Substances 0.000 abstract description 33
- 239000007864 aqueous solution Substances 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 60
- 235000018977 lysine Nutrition 0.000 description 35
- 239000000872 buffer Substances 0.000 description 29
- 238000001914 filtration Methods 0.000 description 25
- 230000001954 sterilising effect Effects 0.000 description 16
- 238000004659 sterilization and disinfection Methods 0.000 description 15
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 14
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 14
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 14
- 235000019766 L-Lysine Nutrition 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000003556 assay Methods 0.000 description 10
- 238000007710 freezing Methods 0.000 description 10
- 230000008014 freezing Effects 0.000 description 10
- 238000011084 recovery Methods 0.000 description 9
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 229940049906 glutamate Drugs 0.000 description 6
- 229960002989 glutamic acid Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 239000000232 Lipid Bilayer Substances 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 229930195714 L-glutamate Natural products 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229940124873 Influenza virus vaccine Drugs 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000002270 exclusion chromatography Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- -1 sucrose disaccharide Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000011100 viral filtration Methods 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008469 cellular response to desiccation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013919 monopotassium glutamate Nutrition 0.000 description 1
- VZUGBLTVBZJZOE-KRWDZBQOSA-N n-[3-[(4s)-2-amino-1,4-dimethyl-6-oxo-5h-pyrimidin-4-yl]phenyl]-5-chloropyrimidine-2-carboxamide Chemical compound N1=C(N)N(C)C(=O)C[C@@]1(C)C1=CC=CC(NC(=O)C=2N=CC(Cl)=CN=2)=C1 VZUGBLTVBZJZOE-KRWDZBQOSA-N 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18151—Methods of production or purification of viral material
Abstract
Un método de preservación de la estabilidad de un virus de la enfermedad de Newcastle que comprenden mantener y/o guardar durante seis meses o más a una temperatura de -4 ºC a -30 ºC una disolución acuosa que comprende: el virus de la enfermedad de Newcastle a una concentración de 106 UFP/ml a 1012 UFP/ml; y sacarosa presente en la disolución a una concentración del 7,5 % (peso/volumen) al 15 % (peso/volumen); en el que la disolución tiene una presión osmótica de 250 mOs o más alta; tiene un pH de 5 a 10; y contiene menos 10 del 0,1 % (peso/volumen) de cloruro sódico, 10 partes por millón o menos de agentes reductores o antioxidantes, y menos de: 1 % (peso/volumen) de dextrano; 0,5 % (peso/volumen) de manitol; 0,1 % (peso/volumen) de sorbitol; 0,01 % (peso/volumen) de Tween; 0,01 % (peso/volumen) de glutamato; 0,5 % (peso/volumen) de polietilenglicol; cloruro de calcio 0,1 mM; 0,5 % (peso/volumen) de fosfatidilcolina; 0,05 % (peso/volumen) de glicina; y 0,01 % (peso/volumen) de fosfato.A method of preserving the stability of a Newcastle disease virus comprising maintaining and / or storing for six months or more at a temperature of -4 ºC to -30 ºC an aqueous solution comprising: the virus of the disease of Newcastle at a concentration of 106 PFU / ml to 1012 PFU / ml; and sucrose present in the solution at a concentration of 7.5% (w / v) to 15% (w / v); wherein the solution has an osmotic pressure of 250 mOs or higher; it has a pH of 5 to 10; and contains less than 0.1% (w / v) 10 of sodium chloride, 10 parts per million or less of reducing agents or antioxidants, and less than: 1% (w / v) dextran; 0.5% (w / v) mannitol; 0.1% (w / v) sorbitol; 0.01% (w / v) Tween; 0.01% (w / v) glutamate; 0.5% (w / v) polyethylene glycol; 0.1mM calcium chloride; 0.5% (w / v) phosphatidylcholine; 0.05% (w / v) glycine; and 0.01% (w / v) phosphate.
Description
DESCRIPCIONDESCRIPTION
Formulaciones de virus envueltos estables y filtrables 5 CAMPO DE LA INVENCIONStable and filterable enveloped virus formulations 5 FIELD OF THE INVENTION
[0001] La presente invention se refiere a la formulation de virus terapeuticos vivos y vacunas de virus vivos. ANTECEDENTES DE LA INVENCION[0001] The present invention relates to the formulation of live therapeutic viruses and live virus vaccines. BACKGROUND OF THE INVENTION
1010
[0002] Solo se ha informado de ejemplos muy limitados para la estabilizacion de vacunas de virus viables liquidas congeladas a -20 °C. La mayorla de estos no emplearon virus envueltos viables purificados (1, 2, 3, 4, 5). Uno de los mayores retos para estabilizar virus envuelto a temperaturas por debajo del punto de congelation es prevenir la rotura flsica de componentes estructurales y funcionales (es decir, protelnas, bicapa lipldica y genoma del[0002] Only very limited examples have been reported for the stabilization of viable liquid virus vaccines frozen at -20 ° C. Most of these did not use purified viable enveloped viruses (1, 2, 3, 4, 5). One of the biggest challenges to stabilize enveloped virus at temperatures below the freezing point is to prevent physical breakage of structural and functional components (i.e., protelnas, lipid bilayer and genome of the
15 virus) durante las etapas de congelacion y almacenamiento. Se ha informado que las protelnas son susceptibles a la desnaturalizacion (6), y las bicapas lipldicas tienen tendencia a la rotura durante la congelacion (7). Se ha informado de varios tipos de excipientes para estabilizar la estructura de la bicapa lipldica y protelnas durante la congelacion y en el estado congelado (6, 7). Estos excipientes incluyen: polioles, sacaridos, tampones, aminoacidos y pollmeros.15 viruses) during the freezing and storage stages. It has been reported that protelnas are susceptible to denaturation (6), and lipid bilayers have a tendency to break during freezing (7). Several types of excipients have been reported to stabilize the structure of the lipid bilayer and proteins during freezing and in the frozen state (6, 7). These excipients include: polyols, saccharides, buffers, amino acids and polymers.
20 [0003] Las principales tareas para la estabilizacion de virus envueltos a temperaturas por debajo del punto de20 [0003] The main tasks for the stabilization of enveloped viruses at temperatures below the point of
congelacion son prevenir la rotura flsica de los componentes estructurales y funcionales durante tanto las etapas de congelacion como de almacenamiento. Los componentes de los virus envueltos incluyen: 1) la membrana de envoltura de la bicapa lipldica; 2) las protelnas codificadas por el genoma viral, y 3) el genoma de ADN o ARN monocatenario o bicatenario.Freezing is preventing physical breakage of structural and functional components during both the freezing and storage stages. The components of the enveloped viruses include: 1) the envelope membrane of the lipid bilayer; 2) the proteins encoded by the viral genome, and 3) the single-stranded or double-stranded DNA or RNA genome.
2525
[0004] Con el fin de garantizar la estabilidad durante el almacenamiento, disoluciones madre de virus infecciosos se han guardado comunmente a temperatura ultra-baja (por ejemplo a < -60 °C) debido a su complejidad. Gould, E.A. ("Methods for long-term Virus Preservation", Molecular Biotechnology Vol. 13, pp.57-66, 1999) ensenan que los virus envueltos con llpidos sobreviven bien a temperaturas ultra-bajas inferiores a -60 °C,[0004] In order to ensure stability during storage, stock solutions of infectious viruses have been commonly stored at ultra-low temperature (for example at <-60 ° C) due to their complexity. Gould, E.A. ("Methods for long-term Virus Preservation", Molecular Biotechnology Vol. 13, pp. 57-66, 1999) teach that viruses enveloped with lipids survive well at ultra-low temperatures below -60 ° C,
30 pero que el almacenamiento a -20 °C debe solo usarse si "la retention de la infectividad del virus no es esencial". D.R. Harper describio las condiciones de almacenamiento para una amplia variedad de virus envueltos y no envueltos ("Virology, Ed. D.R. Harper, BIOS Scientific Publishers Limited, Oxford, UK, 1993). En todos los casos, los virus deben almacenarse a tanto -70 °C en forma llquida como a 4 °C como un liofilo con el fin de retener la infectividad. Las condiciones de almacenamiento para las formulaciones liquidas del virus de la enfermedad de 35 Newcastle se mencionan especlficamente como -70 °C.30 but that storage at -20 ° C should only be used if "virus infectivity retention is not essential". D.R. Harper described the storage conditions for a wide variety of enveloped and non-enveloped viruses ("Virology, Ed. DR Harper, BIOS Scientific Publishers Limited, Oxford, UK, 1993). In all cases, viruses should be stored at both -70 In liquid form at 4 ° C as a lyophil in order to retain infectivity Storage conditions for liquid formulations of the Newcastle disease virus are specifically referred to as -70 ° C.
[0005] Yannarell et al ("Stabilizing cold-adapted influenza virus vaccine under various storage conditions", J. Virol. Meth. Vol. 102, ppm.15-25, 2002) describen condiciones para el almacenamiento de vacuna del virus de la gripe adaptado al frlo a -20 °C usando SPG, una mezcla de sacarosa, fosfato y glutamato (sacarosa 0,218 M, fosfato[0005] Yannarell et al ("Stabilizing cold-adapted influenza virus vaccine under various storage conditions", J. Virol. Meth. Vol. 102, ppm.15-25, 2002) describe conditions for vaccine storage of the virus cold-adapted flu at -20 ° C using SPG, a mixture of sucrose, phosphate and glutamate (0.218 M sucrose, phosphate
40 de potasio monobasico 0,0038 M, fosfato de potasio dibasico 0,0072 M, glutamato de potasio de 0,0049 M). El virus de la gripe preparado en llquido alantoideo para administration intranasal se diluyo al 10 % con una disolucion 10X de SPG. La concentration final de sacarosa en esta mezcla fue del 7,5 %. La presencia de fosfato no ayuda a estabilizar NDV, mientras que el glutamato impide la esterilizacion por filtration y as! ambos compuestos son perjudiciales para la preparation de NDV y el almacenamiento a -20 °C.40 monobasic potassium 0.0038 M, dibasic potassium phosphate 0.0072 M, potassium glutamate 0.0049 M). The influenza virus prepared in allantoid fluid for intranasal administration was diluted to 10% with a 10X solution of SPG. The final sucrose concentration in this mixture was 7.5%. The presence of phosphate does not help stabilize NDV, while glutamate prevents sterilization by filtration and so on! both compounds are harmful for the preparation of NDV and storage at -20 ° C.
45Four. Five
[0006] La administracion parenteral anade una cuestion de formulacion adicional. Por motivos de seguridad, los productos para uso parenteral deben esterilizarse por filtracion a traves de un filtro de 0,2 pm, ya que la esterilizacion terminal no es posible para preparaciones de virus viables. Los viriones de la enfermedad de Newcastle son partlculas pleomorficas, pero aproximadamente esfericas, que oscilan en tamano aproximado de 0,1[0006] The parenteral administration adds an additional formulation question. For safety reasons, products for parenteral use should be sterilized by filtration through a 0.2 pm filter, since terminal sterilization is not possible for viable virus preparations. Newcastle disease virions are pleomorphic particles, but approximately spherical, ranging in size of approximately 0.1
50 a 0,5 pm de diametro. La tasa de recuperation de NDV filtrado a traves de un filtro esteril de 0,2 pm es dependiente de la formulacion y un factor importante a ser considerado para el desarrollo de una formulacion de NDV llquida a - 20 °C.50 to 0.5 pm in diameter. The recovery rate of NDV filtered through a 0.2 pm sterile filter is dependent on the formulation and an important factor to be considered for the development of a liquid NDV formulation at -20 ° C.
[0007] Los factores que afectan la capacidad de NDV para pasar a traves de un filtro esteril de 0,2 pm 55 incluyen el diametro del virus, el tamano de poro del filtro y la adsortividad de NDV al filtro. El diametro aparente de[0007] Factors that affect the ability of NDV to pass through a 0.2 pm sterile filter include the diameter of the virus, the pore size of the filter and the adsorptivity of NDV to the filter. The apparent diameter of
NDV puede ser afectado por: 1) La tonicidad de la formulacion; y 2) la carga superficial de NDV, que puede afectar la configuration molecular y la adsorcion de protelnas o acido nucleico sobre la superficie de NDV en presencia de diferentes tampones.NDV can be affected by: 1) The tonicity of the formulation; and 2) the surface charge of NDV, which can affect the molecular configuration and adsorption of proteins or nucleic acid on the surface of NDV in the presence of different buffers.
[0008] La adsorcion de NDV a la membrana de filtro tambien puede tener un efecto significativo sobre la capacidad del virus para ser esterilizado por filtracion. Varios factores pueden tener un impacto sobre las propiedades superficiales de NDV y as! afectar la adsortividad de NDV al filtro. Estos factores incluyen: 1) pH, 2) fuerza ionica, 3) interacciones superficiales que incluyen interacciones hidrofobas o de van der Waals e[0008] Adsorption of NDV to the filter membrane can also have a significant effect on the ability of the virus to be sterilized by filtration. Several factors can have an impact on the surface properties of NDV and so! affect the adsorptivity of NDV to the filter. These factors include: 1) pH, 2) ionic strength, 3) surface interactions that include hydrophobic or van der Waals interactions and
5 interacciones ionicas y 4) la presencia de agentes tensioactivos tales como tensioactivos.5 ionic interactions and 4) the presence of surfactants such as surfactants.
[0009] El documento US-B1-6 258 362 se refiere a composiciones farmaceuticas secadas estabilizadas dispersables en llquido acuoso o inyeccion.[0009] US-B1-6 258 362 relates to stabilized dried pharmaceutical compositions dispersible in aqueous liquid or injection.
10 [0010] El documento US-A-5 792 643 se refiere a metodos de preservacion de un virus recombinante infeccioso para la posterior reconstitucion.[0010] US-A-5 792 643 refers to methods of preserving an infectious recombinant virus for subsequent reconstitution.
[0011] El documento US-B1-6 290 967 se refiere a estabilizadores de vacuna, formulaciones de vacuna y vacunas liofilizadas con termoestabilidad potenciada.[0011] US-B1-6 290 967 relates to vaccine stabilizers, vaccine formulations and lyophilized vaccines with enhanced thermostability.
15fifteen
[0012] Citas bibliograficas para los antecedentes:[0012] Bibliographic citations for the background:
1. Protocol "Methods for Long Term Virus Preservation", E.A. Gould, Molecular Biotechnology, Vol 13, 1999, pp 5766.1. Protocol "Methods for Long Term Virus Preservation", E.A. Gould, Molecular Biotechnology, Vol 13, 1999, pp 5766.
20 2. T. Barrett, et al., "Growth, Purification and Titration of Influenza Viruses" in Virology: A practical Approach, Ed. B.W.J. Mahy; Raven Press Books, 1985, Ch. 6, pp. 119-146.20 2. T. Barrett, et al., "Growth, Purification and Titration of Influenza Viruses" in Virology: A practical Approach, Ed. B.W.J. Mahy; Raven Press Books, 1985, Ch. 6, pp. 119-146.
3. Virology Lab Fax: Ed. D.R. Harper; Bios Scientific Publishers Limited, 1993.3. Virology Lab Fax: Ed. D.R. Harper; Bios Scientific Publishers Limited, 1993.
4. Lowrence D. Gelb, "Varicella-Zoster Virus" en Virology: Ed. B. N. Fields; Raven Press, 1985, Ch. 28, pp. 591-626.4. Lowrence D. Gelb, "Varicella-Zoster Virus" in Virology: Ed. B. N. Fields; Raven Press, 1985, Ch. 28, pp. 591-626.
5. Stabilizing cold-adapted influenza virus vaccine under various storage conditions: D. A. Yannarell et. al; Journal of 25 Virological Methods; 102: 15-25, 2002.5. Stabilizing cold-adapted influenza virus vaccine under various storage conditions: D. A. Yannarell et. to the; Journal of 25 Virological Methods; 102: 15-25, 2002.
6. Separation of Freezing- and Drying-induced denaturation of Lyophilized Proteins using Stress-Specific Stabilization, Prestrelski, et al., Archives of Biochemistry and Biophysics, Vol. 303, No. 2, June 1993, pp. 465-473.6. Separation of Freezing- and Drying-induced denaturation of Lyophilized Proteins using Stress-Specific Stabilization, Prestrelski, et al., Archives of Biochemistry and Biophysics, Vol. 303, No. 2, June 1993, pp. 465-473.
7. Trehalose expression confers desiccation tolerance on human cells, N. Guo et al., Nature Biotechnology, Vol. 18 Feb. 2000, pp. 168-171.7. Trehalose expression confers desiccation tolerance on human cells, N. Guo et al., Nature Biotechnology, Vol. 18 Feb. 2000, pp. 168-171.
3030
SUMARIO DE LA INVENCIONSUMMARY OF THE INVENTION
[0013] La presente invencion proporciona un metodo de preservacion de la estabilidad de un virus de la enfermedad de Newcastle que comprende mantener y/o guardar durante seis meses o mas a una temperatura de -[0013] The present invention provides a method of preserving the stability of a Newcastle disease virus comprising maintaining and / or storing for six months or more at a temperature of -
35 4 °C a -30 °C una disolucion acuosa que comprende:4 ° C to -30 ° C an aqueous solution comprising:
el virus de la enfermedad de Newcastle a una concentracion de 106 UFP/ml a 1012 UFP/ml;Newcastle disease virus at a concentration of 106 PFU / ml to 1012 PFU / ml;
y sacarosa presente en la disolucion a una concentracion del 7,5 % (peso/volumen) al 15 % (peso/volumen);and sucrose present in the solution at a concentration of 7.5% (weight / volume) to 15% (weight / volume);
4040
en el que la disolucion tiene una presion osmotica de 250 mOs o mas alta; tiene un pH de 5 a 10; y contiene menos del 0,1 % (peso/volumen) de cloruro sodico, 10 partes por millon o menos de agentes reductores o antioxidantes, y menos de:in which the solution has an osmotic pressure of 250 mOs or higher; it has a pH of 5 to 10; and contains less than 0.1% (weight / volume) of sodium chloride, 10 parts per million or less of reducing agents or antioxidants, and less than:
45 1 % (peso/volumen) de dextrano;1% (weight / volume) of dextran;
0,5 % (peso/volumen) de manitol;0.5% (weight / volume) of mannitol;
0,1 % (peso/volumen) de sorbitol;0.1% (weight / volume) of sorbitol;
50fifty
0,01 % (peso/volumen) de Tween;0.01% (weight / volume) of Tween;
0,01 % (peso/volumen) de glutamato;0.01% (weight / volume) of glutamate;
55 0,5 % (peso/volumen) de polietilenglicol;0.5% (weight / volume) of polyethylene glycol;
cloruro de calcio 0,1 mM;0.1 mM calcium chloride;
0,5 % (peso/volumen) de fosfatidilcolina;0.5% (weight / volume) of phosphatidylcholine;
0,05 % (peso/volumen) de glicina; y 0,01 % (peso/volumen) de fosfato. En el presente documento se ensena un sacarido no reductor que es un disacarido y esta presente en una disolucion a una concentracion del 5 % (peso/volumen) al 50 % (peso/volumen), y un monosacarido presente en una disolucion a una concentracion del 2,5 % (peso/volumen) al 25 % (peso/volumen). La disolucion utilizada segun la presente invencion tiene una 5 presion osmotica de aproximadamente 250 mOs o mas alta, y tiene un pH de 5 a 10.0.05% (weight / volume) of glycine; and 0.01% (weight / volume) of phosphate. A non-reducing saccharide is shown herein which is a disaccharide and is present in a solution at a concentration of 5% (weight / volume) to 50% (weight / volume), and a monosaccharide present in a solution at a concentration from 2.5% (weight / volume) to 25% (weight / volume). The solution used according to the present invention has an osmotic pressure of approximately 250 mOs or higher, and has a pH of 5 to 10.
[0014] La presente invencion se basa en el sorprendente hallazgo de que formular virus envueltos en una disolucion acuosa que contiene un sacarido no reductor es una forma eficaz de lograr tanto la esterilizacion por filtracion como la estabilidad a largo plazo a temperaturas moderadamente bajas.[0014] The present invention is based on the surprising finding that formulating viruses wrapped in an aqueous solution containing a non-reducing saccharide is an effective way to achieve both filtration sterilization and long-term stability at moderately low temperatures.
1010
DESCRIPCION DE LA FIGURADESCRIPTION OF THE FIGURE
[0015] Figura 1: La capacidad de filtracion de NDV en diferentes tampones.[0015] Figure 1: The filtering capacity of NDV in different buffers.
15 DESCRIPCION DETALLADA DE LA INVENCION15 DETAILED DESCRIPTION OF THE INVENTION
[0016] Como se usa en el presente documento, el termino de transicion "que comprende" es de extremos abiertos. Una reivindicacion que utiliza este termino puede contener elementos, ademas de aquellos citados en tal reivindicacion. Asl, por ejemplo, las reivindicaciones pueden leerse en pautas de tratamiento que tambien incluyen[0016] As used herein, the term of transition "comprising" is open ended. A claim using this term may contain elements, in addition to those cited in such claim. Thus, for example, the claims can be read in treatment guidelines that also include
20 otros agentes terapeuticos o dosis de virus terapeuticos no especlficamente citadas en su interior, en tanto que esten presentes los elementos citados o sus equivalentes.20 other therapeutic agents or doses of therapeutic viruses not specifically mentioned therein, as long as the aforementioned elements or their equivalents are present.
[0017] Como se usa en el presente documento, "NDV" es una abreviatura para el virus de la enfermedad de Newcastle. Segun la presente invencion, el virus de la enfermedad de Newcastle puede ser de virulencia baja[0017] As used herein, "NDV" is an abbreviation for the Newcastle disease virus. According to the present invention, the Newcastle disease virus can be of low virulence
25 (lentogenico), moderada (mesogenico) o alta (velogenico). El nivel de virulencia se determina segun la prueba del tiempo medio de muerte en huevos (MDT) (Alexander, "Chapter 27: Newcastle Disease" en Laboratory Manual for the Isolation and Identification of Avian Pathogens, 3rd ed., Purchase, et al. eds. (Kendall/Hunt, Iowa), pagina 117). Los virus se clasifican por la prueba de MDT como lentogenicos (MDT>90 horas); mesogenicos (mDt de 60-90 horas); y velogenicos (MDT<60 horas).25 (slowgenic), moderate (mesogenic) or high (velogenic). The virulence level is determined according to the test of the average time of death in eggs (MDT) (Alexander, "Chapter 27: Newcastle Disease" in Laboratory Manual for the Isolation and Identification of Avian Pathogens, 3rd ed., Purchase, et al. eds. (Kendall / Hunt, Iowa), page 117). Viruses are classified by the MDT test as a slow gene (MDT> 90 hours); mesogenic (mDt of 60-90 hours); and velogenics (MDT <60 hours).
3030
[0018] Como se usa en el presente documento, "sustancialmente ninguna" cantidad de un componente o impureza dado significa que el compuesto esta presente en la disolucion a una concentracion de diez partes por millon o menos.[0018] As used herein, "substantially no" amount of a given component or impurity means that the compound is present in the solution at a concentration of ten parts per million or less.
35 [0019] Dada la variabilidad inherente del ensayo de unidades formadoras de placa, un virus se considera "estable" durante un tiempo dado si se pierde menos del 50 % de la infectividad como se mide por el cambio en la cantidad de UFP/ml entre un momento de tiempo previo y un momento de tiempo posterior. El simplemente preservar la actividad enzimatica de protelnas virales individuales, sin tambien preservar la infectividad, no se considera que sea la preservacion de "estabilidad" en el sentido de la presente invencion.[0019] Given the inherent variability of the plaque forming unit assay, a virus is considered "stable" for a given time if less than 50% of infectivity is lost as measured by the change in the amount of PFU / ml. between a moment of previous time and a moment of later time. Simply preserving the enzymatic activity of individual viral proteins, without also preserving infectivity, is not considered to be the preservation of "stability" within the meaning of the present invention.
4040
[0020] La presente invencion utiliza una disolucion acuosa, ya que el agua es esencial en mantener la estructura tridimensional y estabilidad de virus envueltos en la formulacion llquida.[0020] The present invention uses an aqueous solution, since water is essential in maintaining the three-dimensional structure and stability of viruses enveloped in the liquid formulation.
[0021] Disoluciones en las que el virus esta demasiado diluido no son deseables debido a que el virus 45 envuelto es menos estable, mientras que una concentracion de virus alta no parece danar la estabilidad durante el[0021] Solutions in which the virus is too diluted are undesirable because the enveloped virus is less stable, while a high virus concentration does not appear to damage stability during
almacenamiento. En el proceso de congelacion, el virus envuelto se concentrara en la region intersticial, en cuya condition el virus envuelto se considera que esta en un estado altamente concentrado. Segun la presente invencion, la concentracion de virus envuelto de 106 UFP/ml a 1012 UFP/ml, preferentemente de 1 X 1010 UFP/ml a 7 X 1010 UFP/ml.storage. In the freezing process, the enveloped virus will concentrate in the interstitial region, in whose condition the enveloped virus is considered to be in a highly concentrated state. According to the present invention, the concentration of enveloped virus of 106 PFU / ml to 1012 PFU / ml, preferably from 1 X 1010 PFU / ml to 7 X 1010 PFU / ml.
50fifty
[0022] Se ensena en el presente documento que cualquier virus envuelto puede formularse utilizando la disolucion acuosa desvelada en el presente documento. Por ejemplo, pueden usarse paramixovirus tales como virus de la enfermedad de Newcastle. Actualmente se prefiere una cepa mesogenica del virus de la enfermedad de Newcastle.[0022] It is taught herein that any enveloped virus can be formulated using the aqueous solution disclosed herein. For example, paramyxoviruses such as Newcastle disease virus can be used. A mesogenic strain of Newcastle disease virus is currently preferred.
5555
[0023] Hay dos factores importantes a considerar para proteger virus envueltos de la inactivation a temperaturas moderadamente bajas (por ejemplo -20 °C): isotonicidad en el estado llquido y prevention de la desnaturalizacion de las protelnas y la rotura de la membrana lipldica durante la congelacion. Si la presion osmotica es mucho mas baja que el punto isotonico, puede producir que explote la membrana viral. La alta presion osmotica[0023] There are two important factors to consider in order to protect enveloped viruses from inactivation at moderately low temperatures (for example -20 ° C): isotonicity in the liquid state and prevention of denaturation of the proteins and breakage of the lipid membrane during freezing If the osmotic pressure is much lower than the isotonic point, it can cause the viral membrane to explode. Osmotic high pressure
no parece afectar la estabilidad de virus envueltos durante el almacenamiento. Segun la presente invention, es adecuada una presion osmotica de aproximadamente 250 mOs o mas alta. Preferentemente, la presion osmotica es aproximadamente 300 mOs. Cuando la concentration de sacarido en la disolucion esta muy por debajo del 10 % (peso/volumen), puede ser necesario anadir otros excipientes para lograr una presion osmotica deseable.It does not seem to affect the stability of viruses involved during storage. According to the present invention, an osmotic pressure of approximately 250 mOs or higher is suitable. Preferably, the osmotic pressure is approximately 300 mOs. When the concentration of saccharide in the solution is well below 10% (weight / volume), it may be necessary to add other excipients to achieve desirable osmotic pressure.
55
[0024] El otro factor importante que puede afectar la estabilidad es la rotura de la estructura y componentes funcionales durante la congelation y almacenamiento. Sacaridos no reductores, especialmente disacaridos, son los mas eficaces en proteger virus envueltos de la inactivation durante la congelacion. Sin pretender limitarse por el mecanismo, se cree que la protection se produce previniendo la desnaturalizacion de la estructura tridimensional de[0024] The other important factor that can affect stability is the breakage of the structure and functional components during freezing and storage. Non-reducing saccharides, especially disacarids, are the most effective in protecting enveloped viruses from inactivation during freezing. Without pretending to be limited by the mechanism, it is believed that protection is produced by preventing the denaturation of the three-dimensional structure of
10 protelnas y la rotura de la estructura de bicapa lipldica. Tambien pueden usarse sacaridos no reductores para ajustar la presion osmotica en la formulation final. A diferencia, el sacarido reductor lactosa no mostro el mismo efecto estabilizante. Puede utilizarse cualquier sacarido no reductor en la disolucion de la presente invencion. Se ensenan en el presente documento disacaridos, presentes en una disolucion a una concentracion del 5 % (peso/volumen) al 50 % (peso/volumen). En una realization especlfica, el disacarido sacarosa esta presente a una concentracion del 15 7,5 % (peso/volumen) al 15 % (peso/volumen). En una realizacion preferida, el disacarido sacarosa esta presente a una concentracion del 10 % (peso/volumen) al 20 % (peso/volumen), mas especlficamente aproximadamente el 10 % (peso/volumen). Ejemplos de disacaridos adecuados incluyen sacarosa. Se ensenan en el presente documento monosacaridos, presentes en una disolucion a una concentracion del 2,5 % (peso/volumen) al 25 % (peso/volumen); preferentemente del 4 % (peso/volumen) al 7 % (peso/volumen), mas preferentemente 20 aproximadamente del 5 % (peso/volumen).10 protelnas and the breakage of the structure of bilayer lipldica. Non-reducing exits can also be used to adjust the osmotic pressure in the final formulation. In contrast, the lactose reducing saccharide did not show the same stabilizing effect. Any non reducing reducer can be used in the solution of the present invention. Disaccharides, present in a solution at a concentration of 5% (weight / volume) to 50% (weight / volume) are taught herein. In a specific embodiment, the sucrose disaccharide is present at a concentration of 15 7.5% (weight / volume) to 15% (weight / volume). In a preferred embodiment, sucrose disaccharide is present at a concentration of 10% (weight / volume) to 20% (weight / volume), more specifically about 10% (weight / volume). Examples of suitable disacarids include sucrose. Monosaccharides, present in a solution at a concentration of 2.5% (weight / volume) to 25% (weight / volume) are taught herein; preferably 4% (weight / volume) to 7% (weight / volume), more preferably about 5% (weight / volume).
[0025] Segun la presente invencion, la disolucion puede opcionalmente contener ademas lisina (son adecuadas L-lisina y D-lisina) o arginina a una concentracion del 0,1 % (peso/volumen) al 5 % (peso/volumen) o lisina y arginina a una concentracion combinada del 0,1 % (peso/volumen) al 5 % (peso/volumen). Preferentemente,[0025] According to the present invention, the solution may optionally also contain lysine (L-lysine and D-lysine are suitable) or arginine at a concentration of 0.1% (weight / volume) to 5% (weight / volume) or lysine and arginine at a combined concentration of 0.1% (weight / volume) to 5% (weight / volume). Preferably
25 la concentracion de lisina y/o arginina es aproximadamente del 1 % (peso/volumen).The concentration of lysine and / or arginine is approximately 1% (weight / volume).
[0026] La estabilidad del virus esta afectada por el pH. Segun la presente invencion, la disolucion puede tener un pH de 5 a 10, preferentemente de 6,5 a 9, mas preferentemente de 7 a 9, mas especlficamente aproximadamente 7,5.[0026] The stability of the virus is affected by pH. According to the present invention, the solution may have a pH of 5 to 10, preferably 6.5 to 9, more preferably 7 to 9, more specifically about 7.5.
3030
[0027] Diversos compuestos tienen un efecto negativo sobre la estabilidad, capacidad de filtration, o ambos, y debe minimizarse su presencia en la disolucion. Para la estabilidad optima, la disolucion segun la presente invencion no debe contener agentes sustancialmente reductores (por ejemplo, sacaridos reductores, cistelna) o antioxidantes (por ejemplo, EDTA, acido ascorbico). Ciertos otros compuestos son menos perjudiciales y, por consiguiente, no[0027] Various compounds have a negative effect on stability, filtration capacity, or both, and their presence in the solution should be minimized. For optimum stability, the solution according to the present invention should not contain substantially reducing agents (for example, reducing agents, cystel) or antioxidants (for example, EDTA, ascorbic acid). Certain other compounds are less harmful and therefore not
35 necesitan ser excluidos completamente. Por ejemplo, es aceptable que la disolucion utilizada segun la presente invencion contenga hasta el 0,1 % (peso/volumen) de cloruro sodico; 1 % (peso/volumen) de dextrano; 0,5 % (peso/volumen) de manitol; 0,1 % (peso/volumen) de sorbitol; 0,01 % (peso/volumen) de Tween; 0,01 % (peso/volumen) de glutamato; 0,5 % (peso/volumen) de polietilenglicol; cloruro de calcio 0,1 mM; 0,5 % (peso/volumen) de fosfatidilcolina; 0,05 % (peso/volumen) de glicina; y 0,01 % (peso/volumen) de fosfato. Sin 40 embargo es preferible que la disolucion no contenga sustancialmente cloruro sodico, dextrano, manitol, Tween, glutamato, polietilenglicol, cloruro de calcio, fosfatidilcolina, glicina y fosfato. La glicina, ademas de tampones negativamente cargados tales como tampones glutamato o fosfato, no es buena para la esterilizacion por filtracion y recuperacion.35 need to be completely excluded. For example, it is acceptable that the solution used according to the present invention contains up to 0.1% (weight / volume) of sodium chloride; 1% (weight / volume) of dextran; 0.5% (weight / volume) of mannitol; 0.1% (weight / volume) of sorbitol; 0.01% (weight / volume) of Tween; 0.01% (weight / volume) of glutamate; 0.5% (weight / volume) of polyethylene glycol; 0.1 mM calcium chloride; 0.5% (weight / volume) of phosphatidylcholine; 0.05% (weight / volume) of glycine; and 0.01% (weight / volume) of phosphate. However, it is preferable that the solution does not substantially contain sodium chloride, dextran, mannitol, Tween, glutamate, polyethylene glycol, calcium chloride, phosphatidylcholine, glycine and phosphate. Glycine, in addition to negatively charged buffers such as glutamate or phosphate buffers, is not good for sterilization by filtration and recovery.
45 [0028] Cuando la disolucion va a administrarse por via parenteral debe ser esteril. La estabilidad no es crucial para la administration topica o por via oral. Puede, y preferentemente debe, esterilizarse antes del almacenamiento a baja temperatura con un filtro esterilizante de calidad farmaceutica. El metodo preferido para la esterilizacion es la filtracion por tamano usando un filtro que tiene un tamano mas grande que el tamano eficaz del virus envuelto pero mas pequeno que las bacterias. Se prefiere un filtro esteril de 0,2 micrometres. Normalmente, la viscosidad de la 50 disolucion aumenta con la concentracion, que pueden hacer mas diflcil de filtrar el NDV. Para obtener una buena velocidad de recuperation de virus durante la esterilizacion por filtracion, la presion debe preferentemente mantenerse en el intervalo de 10 a 15 psi. Con ajustes de alta viscosidad y baja presion, puede ser muy diflcil filtrar virus envueltos. El problema con la alta viscosidad puede vencerse usando mezcla aseptica despues de la esterilizacion por filtracion del virus. Para evitar la alta viscosidad es preferible no usar altas concentraciones de 55 excipientes. Por ejemplo, el dextrano, un pollmero basado en glucosa, puede afectar la filtracion y recuperacion de virus durante la filtracion final.[0028] When the solution is to be administered parenterally, it must be sterile. Stability is not crucial for topical administration or orally. It can, and preferably should, be sterilized before low temperature storage with a pharmaceutical grade sterilizing filter. The preferred method for sterilization is filtration by size using a filter that has a size larger than the effective size of the enveloped virus but smaller than bacteria. A 0.2 micrometre sterile filter is preferred. Normally, the viscosity of the solution increases with concentration, which can make it harder to filter the NDV. To obtain a good virus recovery rate during filtration sterilization, the pressure should preferably be maintained in the range of 10 to 15 psi. With high viscosity and low pressure settings, it can be very difficult to filter enveloped viruses. The problem with the high viscosity can be overcome using aseptic mixing after sterilization by virus filtration. To avoid high viscosity it is preferable not to use high concentrations of 55 excipients. For example, dextran, a glucose-based polymer, can affect virus filtration and recovery during final filtration.
[0029] Aunque se creyo previamente que las formulaciones llquidas de virus envueltos eran estables solo a temperaturas ultra-bajas tales como -60 °C o -70 °C, sorprendentemente se ha encontrado que los virus envueltos[0029] Although it was previously believed that liquid formulations of enveloped viruses were stable only at ultra-low temperatures such as -60 ° C or -70 ° C, surprisingly it has been found that the enveloped viruses
formulados segun la presente invention son estables durante largos periodos de tiempo a -20 °C. Por ejemplo, los virus envueltos formulados como en la presente invencion son estables a temperaturas de -4 °C a -30 °C, preferentemente -10 °C a -30 °C, mas preferentemente de -15 °C a -25 °C, todavla mas preferentemente a -20 °C. El almacenamiento a aproximadamente -20 °C es conveniente. La capacidad para mantener la estabilidad a -20 °C 5 hara posible que un producto terapeutico sea tenido en existencias en hospitales y farmacias, que normalmente tienen congeladores a -20 °C, pero normalmente no tienen congeladores a -70 °C. Ademas, debido a que los cierres de recipientes tradicionales mantienen mejor flexibilidad a -20 °C que a -70 °C, se asegura el mantenimiento de la esterilidad y, por tanto, la seguridad del paciente por el almacenamiento a -20 °C. Utilizando el metodo de la presente invencion, los virus envueltos son estables durante 6 meses, 12 meses, 24 meses o mas.formulated according to the present invention are stable for long periods of time at -20 ° C. For example, the enveloped viruses formulated as in the present invention are stable at temperatures of -4 ° C to -30 ° C, preferably -10 ° C to -30 ° C, more preferably from -15 ° C to -25 ° C , still more preferably at -20 ° C. Storage at approximately -20 ° C is convenient. The ability to maintain stability at -20 ° C 5 will make it possible for a therapeutic product to be stocked in hospitals and pharmacies, which normally have freezers at -20 ° C, but usually do not have freezers at -70 ° C. In addition, because the closures of traditional containers maintain better flexibility at -20 ° C than at -70 ° C, maintenance of sterility and, therefore, patient safety by storage at -20 ° C is ensured. Using the method of the present invention, the enveloped viruses are stable for 6 months, 12 months, 24 months or more.
1010
[0030] La invencion se entendera mejor por referencia a los siguientes ejemplos, que ilustran, pero no limitan, la invencion descrita en el presente documento. En los siguientes ejemplos, el NDV es una cepa MK107 purificada en placa triple, que es una version atenuada (mesogenica) de la version de virus de la enfermedad de Newcastle, descrita mas completamente en la publication de patente internacional WO 00/62735, publicada el 26 de octubre de[0030] The invention will be better understood by reference to the following examples, which illustrate, but do not limit, the invention described herein. In the following examples, the NDV is a triple plaque purified MK107 strain, which is an attenuated (mesogenic) version of the Newcastle disease virus version, more fully described in the international patent publication WO 00/62735, published on October 26
15 2000 (Pro-Virus, Inc.).15 2000 (Pro-Virus, Inc.).
EJEMPLOSEXAMPLES
[0031] ML se define como 5 % (peso/volumen) de manitol/1 % (peso/volumen) de lisina a pH 8,0[0031] ML is defined as 5% (weight / volume) of mannitol / 1% (weight / volume) of lysine at pH 8.0
20twenty
Ejemplo 1: Estabilidad de NDV en 5 % (peso/volumen) de manitol/1 % (peso/volumen) de disolucion de lisinaExample 1: Stability of NDV in 5% (weight / volume) of mannitol / 1% (weight / volume) of lysine solution
[0032] Se derivo NDV de la cepa mesogenica del virus de la enfermedad de Newcastle Mass-MK107 por purification en placa triple y se produjo por inoculation del virus en la cavidad de llquido alantoideo de huevos de[0032] NDV was derived from the mesogenic strain of Newcastle Mass-MK107 disease virus by triple plate purification and was produced by inoculation of the virus in the allantoic fluid cavity of eggs of
25 pollo embrionados de 10 dlas de edad. Despues de la incubation a 36 °C durante 2 dlas, los huevos se enfriaron y se recogio el llquido alantoideo. El llquido alantoideo recogido se diafiltro con 5 % (peso/volumen) de D-manitol y 1 % (peso/volumen) de L-lisina, tampon a pH 8,0 (ML), se clarifico y se purifico por filtration de flujo tangencial y cromatografla de exclusion por tamano a una concentration de 1 a 4 E+10 UFp/ml, se separo en allcuotas y se guardo a -20 °C. El tltulo de NDV se midio por ensayo en placa y se expreso como la cantidad de unidades 30 formadoras de placa (PFU) de NDV infeccioso por mililitro. Para este ensayo, se sembraron celulas de fibrosarcoma HT1080 humano en placas de cultivo de tejido y se cultivaron a confluencia. Se elimino el medio de crecimiento, se lavaron las monocapas de celulas con medio y se anadieron 0,5 ml de muestra de NDV. Las placas se incubaron balanceando durante 90 minutos a 37 °C y 5 % de CO2. Las monocapas se lavaron como se describe, y se recubrieron 3 ml de medio de agar semi-solido sobre cada pocillo. Los cultivos se incubaron durante 48 horas a 35 37 °C y 5 % de CO2. Las monocapas de celulas se tineron con rojo neutro, se contaron las placas y se determinaron los tltulos de virus, UFP/ml. Los resultados (Tabla I) indicaron que el NDV guardado a -20 °C en 5 % de manitol/1 % de lisina no fue estable, perdiendo en promedio mas del 80 % de actividad. La estabilidad se expreso como el porcentaje de tltulo que queda con respecto al tltulo a tiempo cero.25 embryonated chicken 10 days old. After incubation at 36 ° C for 2 days, the eggs were cooled and the allantoid fluid was collected. The collected allantoid liquid was diafiltered with 5% (weight / volume) of D-mannitol and 1% (weight / volume) of L-lysine, buffer at pH 8.0 (ML), clarified and purified by flow filtration Tangential and exclusion chromatograph per size at a concentration of 1 to 4 E + 10 UFp / ml, separated into allcuotas and stored at -20 ° C. The NDV titer was measured by plaque assay and expressed as the number of plaque forming units (PFU) of infectious NDV per milliliter. For this assay, human HT1080 fibrosarcoma cells were seeded in tissue culture plates and grown at confluence. The growth medium was removed, the cell monolayers were washed with medium and 0.5 ml of NDV sample was added. The plates were incubated balancing for 90 minutes at 37 ° C and 5% CO2. The monolayers were washed as described, and 3 ml of semi-solid agar medium was coated on each well. The cultures were incubated for 48 hours at 35 37 ° C and 5% CO2. The cell monolayers were stained with neutral red, the plates were counted and the virus titers, PFU / ml were determined. The results (Table I) indicated that the NDV stored at -20 ° C in 5% mannitol / 1% lysine was not stable, losing on average more than 80% activity. Stability was expressed as the percentage of the title that remains with respect to the zero-time title.
40 TABLA I: Estabilidad de NDV formulado en 5 % de D-manitol (peso/volumen) y 1 % de L-lisina (peso/volumen) a -TABLE I: Stability of NDV formulated in 5% D-mannitol (weight / volume) and 1% L-lysine (weight / volume) at -
20 °C20 ° C
- Lote N.° Lot No.
- % de actividad restante % of activity remaining
- 4 Meses 4 months
- 8 Meses 12 Meses 18 Meses 24 Meses 8 Months 12 Months 18 Months 24 Months
- 1 one
- 26 NT* 17 NT NT 26 NT * 17 NT NT
- 2 2
- 18 15 9 NT NT 18 15 9 NT NT
- 3 3
- 11 6 0,3 0,9 1,4 11 6 0.3 0.9 1.4
*NT: No probado* NT: Not tested
Ejemplo 2: Estabilidad de NDV en 10 % (peso/volumen) de disolucion de sacarosaExample 2: Stability of NDV in 10% (weight / volume) of sucrose solution
45 [0033] Se preparo NDV por el metodo descrito en el Ejemplo 1, se intercambio de tampon a una disolucion al 10 % (peso/volumen) de sacarosa por filtracion de flujo tangencial y cromatografla de exclusion por tamano, se separo en allcuotas y se guardo a -20 °C. La estabilidad se midio por ensayo en placa como se describe en el Ejemplo 1. Los resultados (Tabla II) indicaron que NDV guardado a -20 °C en 10 % (peso/volumen) de sacarosa fue estable durante hasta 24 meses.[0033] NDV was prepared by the method described in Example 1, buffer was exchanged at a 10% solution (weight / volume) of sucrose by tangential flow filtration and exclusion chromatography per size, separated into allots and stored at -20 ° C. Stability was measured by plaque assay as described in Example 1. The results (Table II) indicated that NDV stored at -20 ° C in 10% (weight / volume) of sucrose was stable for up to 24 months.
TABLA II: Estabilidad de NDV en 10 % (peso/volumen) de formulacion de sacarosa a -20 °CTABLE II: Stability of NDV in 10% (weight / volume) of sucrose formulation at -20 ° C
- Lote N.° Lot No.
- % de actividad restante % of activity remaining
- 3 Meses 3 months
- 6 Meses 12 Meses 18 Meses 24 Meses 6 Months 12 Months 18 Months 24 Months
- 1 one
- 100 100 82 91 100 100 100 82 91 100
- 2 2
- 83 NT 96 NT NT 83 NT 96 NT NT
- 3 3
- 79 93 72 NT NT 79 93 72 NT NT
*NT: No probado* NT: Not tested
Ejemplo 3: Estabilidad de NDV en 10 % (peso/volumen) de disolucion de sacarosa que contiene otros excipientesExample 3: Stability of NDV in 10% (weight / volume) of sucrose solution containing other excipients
55
[0034] Se preparo NDV por el metodo descrito en el Ejemplo 1 y se intercambio de tampon a una disolucion al 1o % (peso/volumen) de sacarosa por filtracion de flujo tangencial y cromatografla de exclusion por tamano. Se prepararon formulaciones separadas de NDV en 10 % (peso/volumen) de sacarosa que contenla un aminoacido mediante la adicion de tanto L-lisina, L-glicina como acido L-glutamico a una concentracion final de 1 % 10 (peso/volumen). Las formulaciones se separaron en allcuotas y se guardaron a -20 °C. La estabilidad se midio por ensayo en placa como se describe en el Ejemplo 1. Los resultados (TABLA III) indicaron que NDV guardado a -20 °C en 10 % (peso/volumen) de sacarosa que contenla 1 % de lisina, 1 % de glicina o 1 % de acido glutamico fue estable durante hasta 14 meses.[0034] NDV was prepared by the method described in Example 1 and buffer was exchanged at a 1% solution (weight / volume) of sucrose by tangential flow filtration and exclusion chromatography per size. Separate formulations of NDV in 10% (weight / volume) of sucrose containing an amino acid were prepared by adding both L-lysine, L-glycine and L-glutamic acid to a final concentration of 1% 10 (weight / volume) . The formulations were separated in allcuotas and stored at -20 ° C. Stability was measured by plaque assay as described in Example 1. The results (TABLE III) indicated that NDV stored at -20 ° C in 10% (weight / volume) of sucrose containing 1% lysine, 1% of glycine or 1% glutamic acid was stable for up to 14 months.
15 TABLA III: Estabilidad de NDV en 10 % (peso/volumen) de sacarosa que contiene aminoacidos a -20 °CTABLE III: Stability of NDV in 10% (weight / volume) of sucrose containing amino acids at -20 ° C
- % de actividad restante % of activity remaining
- NDV/tampon NDV / buffer
- 4 Meses 14 Meses 4 Months 14 Months
- 10 % de sacarosa/1 % (peso/volumen) de L-lisina (pH 6,5) 10% sucrose / 1% (weight / volume) of L-lysine (pH 6.5)
- 100 % 138 % 100% 138%
- 10 % de sacarosa/1 % (peso/volumen) de L-glicina (pH 6,5) 10% sucrose / 1% (weight / volume) of L-glycine (pH 6.5)
- 105 % 115 % 105% 115%
- 10 % de sacarosa/1 % (peso/volumen) de acido L-glutamico (pH 7,9) 10% sucrose / 1% (weight / volume) of L-glutamic acid (pH 7.9)
- 100 % 107 % 100% 107%
Ejemplo 4: Estabilidad de NDV en otras disoluciones de tamponExample 4: Stability of NDV in other buffer solutions
[0035] Se preparo NDV por el metodo descrito en el Ejemplo 1. Porciones de la muestra de NDV se 20 intercambiaron de tampon a diferentes formulaciones que inclulan: 5 % (peso/volumen) de manitol/1 % (peso/volumen) de L-lisina/2 % (peso/volumen) de hidrolizado de gelatina, 10 % (peso/volumen) de trehalosa/1 % (peso/volumen) de L-lisina, acetato sodico 200 mM en 5 % (peso/volumen) de manitol/1 % (peso/volumen) de lisina y 2 % de albumina de suero humano (HSA) en 5 % (peso/volumen) de manitol/1 % (peso/volumen) de lisina, se separaron en allcuotas y se guardaron a -20 °C. La estabilidad se midio por ensayo en placa como se describe en el 25 Ejemplo 1. La adicion de 2 % (peso/volumen) de hidrolizado de gelatina a NDV preparado en 5 % (peso/volumen) de manitol/1 % (peso/volumen) de L-lisina mejoro significativamente la estabilidad en comparacion con NDV preparado en la formulacion de manitol/L-lisina (vease el Ejemplo 1), mientras que la adicion de 2 % de HSA proporciono un nivel mas modesto de proteccion.[0035] NDV was prepared by the method described in Example 1. Portions of the NDV sample were exchanged from buffer to different formulations including: 5% (weight / volume) of mannitol / 1% (weight / volume) of L-lysine / 2% (weight / volume) of gelatin hydrolyzate, 10% (weight / volume) of trehalose / 1% (weight / volume) of L-lysine, 200 mM sodium acetate at 5% (weight / volume) of mannitol / 1% (weight / volume) of lysine and 2% of human serum albumin (HSA) in 5% (weight / volume) of mannitol / 1% (weight / volume) of lysine, separated into alliquots and stored at -20 ° C. Stability was measured by plaque assay as described in Example 1. The addition of 2% (weight / volume) of gelatin hydrolyzate to NDV prepared in 5% (weight / volume) of mannitol / 1% (weight / volume) of L-lysine significantly improved stability compared to NDV prepared in the formulation of mannitol / L-lysine (see Example 1), while the addition of 2% HSA provided a more modest level of protection.
30 TABLA IV: Estabilidad de la formulacion de NDV en tampones que contienen hidrolizado de gelatina, HSA, acetato ____________________________de Na y trehalosa a -20 °C____________________________30 TABLE IV: Stability of NDV formulation in buffers containing gelatin hydrolyzate, HSA, Na acetate and trehalose at -20 ° C ____________________________
- NDV/Tampon NDV / Buffer
- % de actividad restante % of activity remaining
- 4 Meses 4 months
- 8 Meses 12 Meses 18 Meses 24 Meses 8 Months 12 Months 18 Months 24 Months
- 2 % de hidrolizado de gelatina ML 2% ML gelatin hydrolyzate
- 78 71 64 66 80 78 71 64 66 80
- 10 % de trehalosa/1 % de lisina 10% trehalose / 1% lysine
- 35 NT 29 NT NT 35 NT 29 NT NT
- Acetato sodico 200 mM ML 200 mM ML sodium acetate
- 67 52 37 NT NT 67 52 37 NT NT
- 2 % de HSA/ML 2% of HSA / ML
- 65 % 70 % 51 % 43 % NT 65% 70% 51% 43% NT
Ejemplo 5: Estabilidad de NDV en tampones dextrano a -20 °CExample 5: Stability of NDV in dextran buffers at -20 ° C
35 [0036] Se preparo NDV por el metodo descrito en el Ejemplo 1. Se intercambiaron de tampon porciones de la muestra de NDV a diferentes formulaciones que inclulan: 0,9 % (peso/volumen) de NaCl/5 % (peso/volumen) de dextrano y 10 % (peso/volumen) de trehalosa/20 % (peso/volumen) de dextrano. Se encontro que el dextrano proporcionaba un nivel moderado de proteccion a NDV (Tabla V) cuando NDV se almaceno a -20 °C.[0036] NDV was prepared by the method described in Example 1. Portions of the NDV sample were exchanged from buffer to different inclining formulations: 0.9% (weight / volume) NaCl / 5% (weight / volume ) of dextran and 10% (weight / volume) of trehalose / 20% (weight / volume) of dextran. Dextran was found to provide a moderate level of protection to NDV (Table V) when NDV was stored at -20 ° C.
TABLA V: Estabilidad de NDV en tampones dextrano a -20 °CTABLE V: Stability of NDV in dextran buffers at -20 ° C
- % de actividad restante % of activity remaining
- Formulacion Formulation
- 3 Meses 6 Meses 9 Meses 12 Meses 18 Meses 3 Months 6 Months 9 Months 12 Months 18 Months
- NDV 0,9 % de NaCl/5 % de dextrano NDV 0.9% NaCl / 5% dextran
- 61 % 55 % 52 % NA 22 % 61% 55% 52% NA 22%
- NDV 10 % de trehalosa/ 20 % de dextrano (70K) NDV 10% trehalose / 20% dextran (70K)
- 64 % 61 % 50 % 26 % 17 % 64% 61% 50% 26% 17%
Ejemplo 6: Estabilidad de NDV en otras disoluciones de tamponExample 6: Stability of NDV in other buffer solutions
5 [0037] Se purifico NDV por el metodo descrito en el Ejemplo 1, se intercambio de tampon a diferentes tampones (veanse el Ejemplo 4 y 5), se separo en allcuotas y se guardo a -20 °C. La estabilidad se midio por ensayo en placa como se describe en el Ejemplo 1. Los resultados (Tabla VI) indicaron que NDV preparado en estos tampones descritos en la Tabla VI no fue estable cuando se guardo a -20 °C:[0037] NDV was purified by the method described in Example 1, buffer was exchanged to different buffers (see Example 4 and 5), separated into allots and stored at -20 ° C. Stability was measured by plaque assay as described in Example 1. The results (Table VI) indicated that NDV prepared in these buffers described in Table VI was not stable when stored at -20 ° C:
10 El resto de esta pagina se ha dejado intencionadamente en blanco.10 The rest of this page is intentionally left blank.
TABLA VI: NDV en tampones que muestran mala estabilidad a -20 °CTABLE VI: NDV in buffers that show poor stability at -20 ° C
- Formulacion Formulation
- % de actividad restante % of activity remaining
- 4 M 4 m
- 8 M 12 M 8 M 12 M
- 5 % (peso/volumen) de manitol/1 % (peso/volumen) de L-Lisina 5% (weight / volume) of mannitol / 1% (weight / volume) of L-Lysine
- 18 % 15 % 9 % 18% 15% 9%
- 0,1 % (peso/volumen) de Tween/ML 0.1% (weight / volume) of Tween / ML
- <1 % NT NT <1% NT NT
- 10 % (peso/volumen) de disolucion de lactosa 10% (weight / volume) of lactose solution
- <1 % NT NT <1% NT NT
- 2 % (peso/volumen) de gelatina/5 % (peso/volumen) de manitol/ 1 % (peso/volumen) de lisina 2% (weight / volume) of gelatin / 5% (weight / volume) of mannitol / 1% (weight / volume) of lysine
- 13 % NT NT 13% NT NT
- 1 % (peso/volumen) de arginina / 5 % (peso/volumen) de disolucion de manitol 1% (weight / volume) of arginine / 5% (weight / volume) of mannitol solution
- 2,3 % NT NT 2.3% NT NT
- 1 % (peso/volumen) de acido glutamico/5 % (peso/volumen) de manitol 1% (weight / volume) of glutamic acid / 5% (weight / volume) of mannitol
- <1 % NT NT <1% NT NT
- 5 % (peso/volumen) PEG/5 % (peso/volumen) de manitol/ 1 % (peso/volumen) de lisina 5% (weight / volume) PEG / 5% (weight / volume) of mannitol / 1% (weight / volume) of lysine
- 3,7 % NT NT 3.7% NT NT
- CaCl2 10 mM /ML 10 mM / ML CaCl2
- 6 % NT NT 6% NT NT
- 5 % de fosfatidilcolina/ ML 5% phosphatidylcholine / ML
- 14 % NT NT 14% NT NT
- 1 % de glicina/5 % (peso/volumen) de manitol 1% glycine / 5% (weight / volume) of mannitol
- 5 % NT NT 5% NT NT
- 0,05 % de EDTA/5 % (peso/volumen) de manitol/ 1 % (peso/volumen) de lisina 0.05% EDTA / 5% (weight / volume) of mannitol / 1% (weight / volume) of lysine
- 31 % 17 % NA 31% 17% NA
- *NT: No probado * NT: Not tested
Ejemplo 7: Esterilizacion por filtracion de NDV preparado en manitolExample 7: Sterilization by filtration of NDV prepared in mannitol
15fifteen
[0038] Se preparo NDV en 5 % (peso/volumen) de manitol/1 % (peso/volumen) de lisina como se describe en el Ejemplo 1. Se dializo una porcion (como) en 5 % (peso/volumen) de manitol. Se anadio dextrano a otra porcion de NDV ML para preparar una muestra de NDV en ML que contenla 10 % (peso/volumen) de dextrano. Estas muestras se probaron para su capacidad para someterse a esterilizacion por filtracion pasando aproximadamente 30 ml de 20 cada muestra secuencialmente a traves de un prefiltro Sartobran™ de 0,45 um y un filtro Sartobran™ de 0,22 um bajo 15 psi. Los filtros se humedecieron previamente con tampon ML. Los filtrantes de cada muestra se recogieron y se analizaron por ensayo en placa para la cantidad total de actividad de placas virales recuperada (UFP) como se describe en el Ejemplo 1. NDV preparado en tampon ML o en 5 % (peso/volumen) de manitol se filtro facilmente, mientras que NDV preparado en tampon ML que contenla 10 % (peso/volumen) de dextrano no paso a traves del 25 filtro apreciablemente (Tabla VII).[0038] NDV was prepared in 5% (weight / volume) of mannitol / 1% (weight / volume) of lysine as described in Example 1. A portion (as) was dialyzed in 5% (weight / volume) of Mannitol Dextran was added to another portion of NDV ML to prepare a sample of NDV in ML containing 10% (weight / volume) of dextran. These samples were tested for their ability to undergo filtration sterilization by passing approximately 30 ml of each sample sequentially through a 0.45 um Sartobran ™ prefilter and a 0.22 um Sartobran ™ filter under 15 psi. The filters were previously moistened with ML buffer. Filters from each sample were collected and analyzed by plaque assay for the total amount of recovered viral plaque activity (PFU) as described in Example 1. NDV prepared in ML buffer or at 5% (weight / volume) of Mannitol was easily filtered, while NDV prepared in ML buffer containing 10% (weight / volume) of dextran did not pass through the filter appreciably (Table VII).
TABLA VII: Resumen de los estudios de filtracion para NDV que contiene manitol/lisina/dextranoTABLE VII: Summary of filtration studies for NDV containing mannitol / lysine / dextran
- Formulacion Formulation
- Recuperacion total (carga en porcentaje, normalizada) Total recovery (percentage charge, normalized)
- ML ML
- 82 ± 17 82 ± 17
- 5 % (peso/volumen) de manitol 5% (weight / volume) of mannitol
- 83 ± 17 83 ± 17
- 10 % (peso/volumen) de dextrano/5 % (peso/volumen) de manitol/1 % (peso/volumen) de lisina 10% (weight / volume) of dextran / 5% (weight / volume) of mannitol / 1% (weight / volume) of lysine
- 4 ± 3 4 ± 3
Ejemplo 8: Esterilizacion por filtracion de NDV en tampon manitol que contiene lisina/fosfato/NaClExample 8: Sterilization by filtration of NDV in mannitol buffer containing lysine / phosphate / NaCl
[0039] Se preparo NDV como se describe en el Ejemplo 1, se intercambio a los tampones descritos en la Figura 1 y se probo para su capacidad para someterse a esterilizacion por filtracion como se describe en el Ejemplo 7. Los filtros se humedecieron previamente con el tampon usado en la formulacion. Para cada formulacion, se[0039] NDV was prepared as described in Example 1, exchanged to the buffers described in Figure 1 and tested for its ability to undergo filtration sterilization as described in Example 7. The filters were pre-moistened with the buffer used in the formulation. For each formulation, it
5 recogio el volumen de tampon de NDV que paso a traves del filtro y se calculo el volumen acumulado. El NDV preparado en 5 % (peso/volumen) de manitol/1 % (peso/volumen) de lisina se filtro bien. El NDV preparado en 324 mOs de NaCl se filtro algo, pero NDV no se esterilizo por filtracion bien cuando se preparo en 5 % (peso/volumen) de manitol que contenla 1 % (peso/volumen) de L-lisina, fosfato 20 mm o 5 % (peso/volumen) de manitol/1 % (peso/volumen) de lisina que contenla 0,9 % de NaCl o fosfato 20 mM.5 collected the volume of NDV buffer that passed through the filter and the accumulated volume was calculated. The NDV prepared in 5% (weight / volume) of mannitol / 1% (weight / volume) of lysine was well filtered. The NDV prepared in 324 mOs of NaCl was somewhat filtered, but NDV was not sterilized by filtration well when prepared in 5% (weight / volume) of mannitol containing 1% (weight / volume) of L-lysine, 20 mm phosphate or 5% (weight / volume) of mannitol / 1% (weight / volume) of lysine containing 0.9% NaCl or 20 mM phosphate.
1010
Ejemplo 9: Esterilizacion por filtracion de NDV preparado en tampon que contiene 10 % (peso/volumen) de sacarosa o 10 % (peso/volumen) de trehalosaExample 9: Sterilization by filtration of NDV prepared in buffer containing 10% (weight / volume) of sucrose or 10% (weight / volume) of trehalose
[0040] Se prepararon muestras de NDV como se describe en el Ejemplo 1 y se diafiltraron en 10 % 15 (peso/volumen) de sacarosa o 10 % (peso/volumen) de trehalosa. A partir de estas disoluciones se prepararon[0040] NDV samples were prepared as described in Example 1 and diafiltered in 10% (weight / volume) of sucrose or 10% (weight / volume) of trehalose. From these solutions they were prepared
muestras adicionales de NDV que contenlan 10 % (peso/volumen) de sacarosa / 1 % de L-lisina, 10 % (peso/volumen) de sacarosa / 1 % de L-lisina /10 % (peso/volumen) de dextrano y 10 % (peso/volumen) de trehalosa / 1 % de L-lisina mediante la adicion de los componentes respectivos. Las muestras se probaron para su capacidad para someterse a esterilizacion por filtracion como se describe en el Ejemplo 6. NDV preparado en 10 % 20 (peso/volumen) de sacarosa, 10 % (peso/volumen) de sacarosa / 1 % (peso/volumen) de L-lisina o 10 % (peso/volumen) de trehalosa se esterilizo por filtracion con una tasa de recuperacion muy buena. NDV preparado en 10 % (peso/volumen) de trehalosa /1 % (peso/volumen) de L-lisina se filtro con una tasa de recuperacion razonable, mientras que NDV preparado en 10 % (peso/volumen) de sacarosa / 1 % (peso/volumen) de L-lisina / 10 % (peso/volumen) de dextrano se esterilizo mal por filtracion (Tabla VIII).additional samples of NDV containing 10% (weight / volume) of sucrose / 1% of L-lysine, 10% (weight / volume) of sucrose / 1% of L-lysine / 10% (weight / volume) of dextran and 10% (weight / volume) of trehalose / 1% of L-lysine by the addition of the respective components. The samples were tested for their ability to undergo filtration sterilization as described in Example 6. NDV prepared in 10% 20 (weight / volume) of sucrose, 10% (weight / volume) of sucrose / 1% (weight / volume) of L-lysine or 10% (weight / volume) of trehalose was sterilized by filtration with a very good recovery rate. NDV prepared in 10% (weight / volume) of trehalose / 1% (weight / volume) of L-lysine was filtered with a reasonable recovery rate, while NDV prepared in 10% (weight / volume) of sucrose / 1% (weight / volume) of L-lysine / 10% (weight / volume) of dextran was poorly sterilized by filtration (Table VIII).
2525
TABLA VIII: Resumen de estudios de filtracion para NDV que contiene sacarosa/trehalosa/lisina/dextranoTABLE VIII: Summary of filtration studies for NDV containing sucrose / trehalose / lysine / dextran
- Formulacion Formulation
- Recuperacion total (porcentaje de carga, normalizado) Total recovery (percentage of charge, normalized)
- 10 % de sacarosa 10% sucrose
- 69 ± 7 69 ± 7
- 10 % de sacarosa/1 % de lisina 10% sucrose / 1% lysine
- 83 ± 3 83 ± 3
- 10 % de trehalosa 10% Trehalose
- 74 ± 3 74 ± 3
- 10 % de trehalosa/1 % de lisina 10% trehalose / 1% lysine
- 60 ± 7 60 ± 7
- 10 % de dextrano/10 % de sacarosa/1 % de lisina 10% dextran / 10% sucrose / 1% lysine
- 11 ± 1 11 ± 1
Ejemplo 10: Esterilizacion por filtracion de NDV preparado en 10 % de sacarosa que contiene 1 % de L-lisina, 1 % L-glutamato o 1 % de L-glicinaExample 10: Sterilization by filtration of NDV prepared in 10% sucrose containing 1% L-lysine, 1% L-glutamate or 1% L-glycine
3030
[0041] Se prepararon muestras de NDV como se describe en el Ejemplo 1 y se diafiltraron en 10 % (peso/volumen) de sacarosa. Este material se separo en cuatro porciones. Se anadio L-lisina, L-glutamato o L-glicina a cada una de las tres de estas porciones para producir muestras que contenlan 10 % (peso/volumen) de sacarosa y 1 % (peso/volumen) de L-lisina, L-glutamato o L-glicina. Estas muestras se probaron para su capacidad para[0041] NDV samples were prepared as described in Example 1 and diafiltered in 10% (weight / volume) of sucrose. This material was separated into four portions. L-lysine, L-glutamate or L-glycine was added to each of the three of these portions to produce samples containing 10% (weight / volume) of sucrose and 1% (weight / volume) of L-lysine, L -glutamate or L-glycine. These samples were tested for their ability to
35 someterse a esterilizacion por filtracion como se describe en el Ejemplo 6. NDV preparado en 10 % (peso/volumen) de sacarosa o 10 % (peso/volumen) de sacarosa que contenla 1 % de L-lisina se filtro facilmente mientras que NDV preparado en 10 % (peso/volumen) de sacarosa que contenla 1 % (peso/volumen) de L-glutamato o glicina se filtro marginalmente (Tabla IX).Undergoing filtration sterilization as described in Example 6. NDV prepared in 10% (weight / volume) of sucrose or 10% (weight / volume) of sucrose containing 1% L-lysine was easily filtered while NDV prepared in 10% (weight / volume) of sucrose containing 1% (weight / volume) of L-glutamate or glycine is marginally filtered (Table IX).
40 TABLA IX: Resumen de estudios de filtracion para NDV que contiene sacarosa/lisina/acido glutamico/glicina40 TABLE IX: Summary of filtration studies for NDV containing sucrose / lysine / glutamic acid / glycine
- Formulacion Formulation
- Recuperacion total (porcentaje de carga, normalizado) Total recovery (percentage of charge, normalized)
- 10 % de sacarosa 10% sucrose
- 66 ± 11 66 ± 11
- 10 % de sacarosa/1 % de lisina 10% sucrose / 1% lysine
- 55 ± 16 55 ± 16
- 10 % de sacarosa/1 % de acido glutamico 10% sucrose / 1% glutamic acid
- 35 ± 5 35 ± 5
- 10 % de sacarosa/1 % de glicina 10% sucrose / 1% glycine
- 25 ± 1 25 ± 1
Ejemplo 11: Estabilidad de NDV en 10 % de sacarosa/lisina a diferentes pHExample 11: Stability of NDV in 10% sucrose / lysine at different pH
[0042] Se preparo NDV por los metodos descritos en el Ejemplo 1 y se intercambio de tampon a 10 % 45 (peso/volumen) de sacarosa. Se prepararon muestras de prueba de NDV/10 % de disolucion de sacarosa a[0042] NDV was prepared by the methods described in Example 1 and exchanged buffer at 10% (weight / volume) sucrose. NDV test samples / 10% sucrose solution were prepared at
diferentes pH anadiendo tampon sacarosa/lisina de pH ajustado (diferentes pH) y se guardaron a -20 °C. Se probo la estabilidad de las muestras por ensayo en placa como se describe en el Ejemplo 1. Los resultados indicaron que NDV/10 % de disolucion de sacarosa es mas estable en el intervalo de pH 7,3 a pH 8,8 que a pH mas bajo.different pHs by adding sucrose / lysine buffer of adjusted pH (different pH) and stored at -20 ° C. The stability of the samples was tested by plaque assay as described in Example 1. The results indicated that NDV / 10% sucrose solution is more stable in the range of pH 7.3 to pH 8.8 than to pH lower.
TABLA X: Estabilidad de NDV formulado en 10 % de sacarosa (peso/volumen)/1 % de lisina (peso/volumen) aTABLE X: Stability of NDV formulated in 10% sucrose (weight / volume) / 1% lysine (weight / volume) at
- diferentes different
- pH a -20 °C pH at -20 ° C
- Formulacion (0-fecha: 22/10/05) Formulation (0-date: 10/22/05)
- % de actividad restante % of activity remaining
- 6 Meses 6 months
- 6 Meses 6 months
- 9 Meses 12 Meses 9 Months 12 Months
- NDV 10 % de control de sacarosa (pH 5,7) NDV 10% sucrose control (pH 5.7)
- 41 % 26 % 35 % 29 % 41% 26% 35% 29%
- NDV Sac/1 % de lisina pH 5,3 NDV Sac / 1% lysine pH 5.3
- 50 % 38 % 28 % 42 % 50% 38% 28% 42%
- NDV Sac/1 % de lisina pH 5,7 NDV Sac / 1% lysine pH 5.7
- 68 % 71 % 52 % 39 % 68% 71% 52% 39%
- NDV Sac/1 % de lisina pH 6,3 NDV Sac / 1% lysine pH 6.3
- 109 % 58 % 52 % 52 % 109% 58% 52% 52%
- NDV Sac/1 % de lisina pH 6,6 NDV Sac / 1% lysine pH 6.6
- 49 % 49 % 51 % 35 % 49% 49% 51% 35%
- NDV Sac/1 % de lisina pH 7,3 NDV Sac / 1% lysine pH 7.3
- 72 % 85 % 64 % 62 % 72% 85% 64% 62%
- NDV Sac/1 % de lisina pH 8,3 NDV Sac / 1% lysine pH 8.3
- 89 % 68 % 74 % 58 % 89% 68% 74% 58%
- NDV Sac/1 % de lisina pH 8,8 NDV Sac / 1% lysine pH 8.8
- 69 % 64 % TNTC 64 % 69% 64% TNTC 64%
- TNTC: Demasiado numerosa como para contarla TNTC: Too numerous to tell
Ejemplo 12: Estabilidad de NDV en diferentes concentraciones de sacarosaExample 12: Stability of NDV at different concentrations of sucrose
[0043] Se preparo NDV por los metodos descritos en el Ejemplo 1 y se intercambio de tampon a 10 % 10 (peso/volumen) de sacarosa. Se prepararon muestras de prueba de NDV a diferente concentracion de disolucion de sacarosa anadiendo diferente sacarosa concentrada o anadiendo agua para inyeccion y se guardaron a -20 °C. Los tltulos finales de cada formulacion se ajustaron a aproximadamente 2E10. Se probo la estabilidad de las muestras por ensayo en placa como se describe en el Ejemplo 1. Los resultados indican que el virus preparado en 10 al 20 % (peso/volumen) de sacarosa fue mas estable que el virus preparado en concentraciones de sacarosa mas bajas.[0043] NDV was prepared by the methods described in Example 1 and 10% buffer (weight / volume) of sucrose was exchanged. NDV test samples were prepared at different concentration of sucrose solution by adding different concentrated sucrose or adding water for injection and stored at -20 ° C. The final titles of each formulation were adjusted to approximately 2E10. The stability of the samples was tested by plaque assay as described in Example 1. The results indicate that the virus prepared in 10 to 20% (weight / volume) of sucrose was more stable than the virus prepared in sucrose concentrations plus low.
15fifteen
TABLA XI: Efecto de la concentracion de sacarosa sobre la estabilidad de NDV a -20 °CTABLE XI: Effect of sucrose concentration on the stability of NDV at -20 ° C
- Formulacion Formulation
- % de actividad restante % of activity remaining
- 6 Meses 6 months
- 9 Meses 9 months
- NDV 2,5 % (peso/volumen) de sacarosa 2.5% NDV (weight / volume) of sucrose
- 63 % 51 % 63% 51%
- NDV 5,0 % (peso/volumen) de sacarosa NDV 5.0% (weight / volume) of sucrose
- 67 % 76 % 67% 76%
- NDV 7,5 % (peso/volumen) de sacarosa NDV 7.5% (weight / volume) of sucrose
- 60 % 55 % 60% 55%
- NDV 10 % (peso/volumen) de sacarosa NDV 10% (weight / volume) of sucrose
- 100 % 84 % 100% 84%
- NDV 15 % (peso/volumen) de sacarosa NDV 15% (weight / volume) of sucrose
- 81 % 71 % 81% 71%
- NDV 20 % (peso/volumen) de sacarosa NDV 20% (weight / volume) of sucrose
- 89 % 83 % 89% 83%
Claims (9)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62534904P | 2004-11-05 | 2004-11-05 | |
| US625349P | 2004-11-05 | ||
| PCT/US2005/040149 WO2006052813A2 (en) | 2004-11-05 | 2005-11-04 | Stable and filterable enveloped virus formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2619936T3 true ES2619936T3 (en) | 2017-06-27 |
Family
ID=36337060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05817250.3T Active ES2619936T3 (en) | 2004-11-05 | 2005-11-04 | Stable and filterable enveloped virus formulations |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7914979B2 (en) |
| EP (1) | EP1807511B1 (en) |
| JP (2) | JP5110696B2 (en) |
| KR (1) | KR101400379B1 (en) |
| CN (1) | CN101052714B (en) |
| AU (1) | AU2005304866B2 (en) |
| CA (1) | CA2584815C (en) |
| ES (1) | ES2619936T3 (en) |
| IL (1) | IL182856A (en) |
| MX (1) | MX2007005379A (en) |
| RU (1) | RU2458125C2 (en) |
| WO (1) | WO2006052813A2 (en) |
| ZA (1) | ZA200703194B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2461679B1 (en) | 2009-07-28 | 2019-02-13 | GE Healthcare Bio-Sciences Corp. | Vaccine stabilizer |
| CN101979516B (en) * | 2010-10-19 | 2013-07-03 | 李海波 | Virus sampling liquid composition |
| MX349294B (en) * | 2010-12-02 | 2017-07-21 | Oncolytics Biotech Inc | Lyophilized viral formulations. |
| CN103347535B (en) * | 2010-12-02 | 2015-11-25 | 昂科利蒂克斯生物科技公司 | Liquid virus preparation |
| WO2013095965A1 (en) * | 2011-12-19 | 2013-06-27 | Wellstat Biologics Corporation | Stable storage of enveloped viruses in histidine aqueous solution |
| FR3010720B1 (en) | 2013-09-16 | 2017-08-11 | Genethon | PROCESS FOR PRODUCING ENVELOPED VIRUSES |
| FR3014901B1 (en) | 2013-12-17 | 2017-06-09 | Genethon | PROCESS FOR PURIFYING ENHANCED VIRUSES OR VIRTORS |
| AR099470A1 (en) * | 2014-02-17 | 2016-07-27 | Intervet Int Bv | LIQUID CORRAL BIRD VIRUS VACCINES |
| TWI670085B (en) * | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | Swine virus vaccines that are liquid stable |
| ES2753364T3 (en) | 2014-12-01 | 2020-04-08 | Transgene Sa | Stable liquid formulations of vaccinia virus |
| US20190134190A1 (en) | 2016-05-04 | 2019-05-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| CA3062549A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| EP3624851A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK124340B (en) | 1969-11-29 | 1972-10-09 | Takeda Chemical Industries Ltd | Method for producing strong attenuated, live Newcastle disease virus vaccine. |
| JPS57114527A (en) * | 1979-10-29 | 1982-07-16 | Merck & Co Inc | Vaccine stabilizer |
| PT71926B (en) * | 1979-10-29 | 1982-03-31 | Merck & Co Inc | Process for preparing a liquid vaccine comprising a stabilizer |
| US4338335A (en) * | 1980-02-05 | 1982-07-06 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
| DD299213A7 (en) | 1988-05-04 | 1992-04-09 | Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De | METHOD FOR STABILIZING A LIVE VIRUS VACCINE AGAINST TEMPERATURE EFFECT |
| US6165500A (en) * | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
| US5602023A (en) * | 1992-03-24 | 1997-02-11 | Csatary; Laszlo K. | Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same |
| AU7971194A (en) * | 1993-10-12 | 1995-05-04 | Chiron Corporation | Methods for preserving recombinant viruses |
| FR2742756B1 (en) | 1995-12-22 | 1998-04-03 | Pasteur Merieux Serums Vacc | STABILIZERS FOR LIVE VACCINES, VACCINES CONTAINING SAME, AND PROCESSES FOR THEIR PREPARATION |
| ZA973642B (en) * | 1996-04-26 | 1997-11-25 | Merck & Co Inc | DNA vaccine formulations. |
| WO1998008934A1 (en) * | 1996-08-30 | 1998-03-05 | Life Technologies, Inc. | Serum-free mammalian cell culture medium, and uses thereof |
| US6290967B1 (en) * | 1996-12-20 | 2001-09-18 | Merck & Co., Inc. | Stabilizers for lyophilized vaccines |
| CN1063971C (en) * | 1997-09-24 | 2001-04-04 | 中国兽药监察所 | Method for preparing freeze-dried live vaccine for animal use |
| WO2000062735A2 (en) | 1999-04-15 | 2000-10-26 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| GB9808922D0 (en) * | 1998-04-24 | 1998-06-24 | Cantab Pharmaceuticals Res Ltd | Virus preparations |
| CA2342849C (en) * | 1998-09-04 | 2013-01-29 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant aav vectors |
| US6896894B2 (en) * | 2001-10-30 | 2005-05-24 | Battelle Memorial Institute | Proteins stabilized with polysaccharide gums |
| US20030153065A1 (en) | 2002-01-14 | 2003-08-14 | Genvec, Inc. | Composition and method for maintaining non-enveloped viral vectors |
| WO2005058356A2 (en) * | 2003-12-17 | 2005-06-30 | Wyeth | Methods for porducing storage stable viruses and immunogenic compositions thereof |
-
2005
- 2005-11-04 MX MX2007005379A patent/MX2007005379A/en active IP Right Grant
- 2005-11-04 RU RU2007120758/10A patent/RU2458125C2/en not_active IP Right Cessation
- 2005-11-04 KR KR1020077012753A patent/KR101400379B1/en not_active IP Right Cessation
- 2005-11-04 CN CN200580037889XA patent/CN101052714B/en not_active Expired - Fee Related
- 2005-11-04 CA CA2584815A patent/CA2584815C/en not_active Expired - Fee Related
- 2005-11-04 WO PCT/US2005/040149 patent/WO2006052813A2/en active Application Filing
- 2005-11-04 AU AU2005304866A patent/AU2005304866B2/en not_active Ceased
- 2005-11-04 ES ES05817250.3T patent/ES2619936T3/en active Active
- 2005-11-04 JP JP2007539369A patent/JP5110696B2/en active Active
- 2005-11-04 EP EP05817250.3A patent/EP1807511B1/en active Active
- 2005-11-04 US US11/718,348 patent/US7914979B2/en active Active
-
2007
- 2007-04-18 ZA ZA200703194A patent/ZA200703194B/en unknown
- 2007-04-29 IL IL182856A patent/IL182856A/en not_active IP Right Cessation
-
2012
- 2012-08-13 JP JP2012179515A patent/JP2012214518A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008518972A (en) | 2008-06-05 |
| RU2007120758A (en) | 2008-12-10 |
| RU2458125C2 (en) | 2012-08-10 |
| WO2006052813A3 (en) | 2006-09-14 |
| JP5110696B2 (en) | 2012-12-26 |
| CN101052714A (en) | 2007-10-10 |
| MX2007005379A (en) | 2007-07-04 |
| US7914979B2 (en) | 2011-03-29 |
| CN101052714B (en) | 2012-01-11 |
| JP2012214518A (en) | 2012-11-08 |
| EP1807511B1 (en) | 2017-01-04 |
| EP1807511A4 (en) | 2009-05-13 |
| IL182856A (en) | 2015-03-31 |
| CA2584815A1 (en) | 2006-05-18 |
| AU2005304866B2 (en) | 2010-04-01 |
| AU2005304866A1 (en) | 2006-05-18 |
| CA2584815C (en) | 2014-03-25 |
| ZA200703194B (en) | 2008-08-27 |
| KR101400379B1 (en) | 2014-05-28 |
| WO2006052813A2 (en) | 2006-05-18 |
| EP1807511A2 (en) | 2007-07-18 |
| IL182856A0 (en) | 2007-08-19 |
| KR20070085818A (en) | 2007-08-27 |
| US20080166784A1 (en) | 2008-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2619936T3 (en) | Stable and filterable enveloped virus formulations | |
| JP4550421B2 (en) | Composition for the preservation of viruses | |
| ES2621511T3 (en) | Methods and compositions for live attenuated viruses | |
| ES2367833T3 (en) | PROCEDURE FOR THE PREPARATION OF AN ACTIVE COMPONENT OF A DRUG OR AGENT OF DIAGNOSIS IN CULTURE IN SUSPENSION OF MDCK CELLS. | |
| ES2370675T3 (en) | PROCEDURE TO PROTECT VIRAL PARTICLES. | |
| KR0149677B1 (en) | Stabilized live vaccine | |
| US9028839B2 (en) | Stabilizing excipient for inactivated whole virus vaccine | |
| EP2552478B1 (en) | Excipients for stabilising viral particles | |
| ES2224422T3 (en) | RECOVERY OF A VIRUS FROM A CELL CULTURE USING A HYPERTONIC SALT DISSOLUTION. | |
| EP2852662A2 (en) | Herpesvirus compositions and related methods | |
| JP6426695B2 (en) | Compositions and methods for attenuated live alphavirus formulations | |
| WO2021020446A1 (en) | Composition containing herpes simplex virus | |
| WO2013095965A1 (en) | Stable storage of enveloped viruses in histidine aqueous solution | |
| NZ554550A (en) | Stable and filterable enveloped virus formulations | |
| AU2002366654B2 (en) | Composition for viral preservation |